CA3150003A1 - Methods for treating hyperphenylalaninemia - Google Patents

Methods for treating hyperphenylalaninemia Download PDF

Info

Publication number
CA3150003A1
CA3150003A1 CA3150003A CA3150003A CA3150003A1 CA 3150003 A1 CA3150003 A1 CA 3150003A1 CA 3150003 A CA3150003 A CA 3150003A CA 3150003 A CA3150003 A CA 3150003A CA 3150003 A1 CA3150003 A1 CA 3150003A1
Authority
CA
Canada
Prior art keywords
day
sepiapterin
subject
per liter
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3150003A
Other languages
English (en)
French (fr)
Inventor
Niel SMITH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics MP Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3150003A1 publication Critical patent/CA3150003A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3150003A 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia Pending CA3150003A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905720P 2019-09-25 2019-09-25
US62/905,720 2019-09-25
PCT/US2020/052871 WO2021062264A1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Publications (1)

Publication Number Publication Date
CA3150003A1 true CA3150003A1 (en) 2021-04-01

Family

ID=72827023

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3150003A Pending CA3150003A1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Country Status (22)

Country Link
US (1) US20220362249A1 (https=)
EP (1) EP4034122B1 (https=)
JP (2) JP7661315B2 (https=)
KR (1) KR20220070477A (https=)
CN (1) CN114650825A (https=)
BR (1) BR112022003719A2 (https=)
CA (1) CA3150003A1 (https=)
DK (1) DK4034122T3 (https=)
ES (1) ES3041002T3 (https=)
FI (1) FI4034122T3 (https=)
HR (1) HRP20251268T1 (https=)
HU (1) HUE073483T2 (https=)
IL (1) IL291565B1 (https=)
JO (1) JOP20220042A1 (https=)
LT (1) LT4034122T (https=)
MX (1) MX2022003585A (https=)
PL (1) PL4034122T3 (https=)
PT (1) PT4034122T (https=)
RS (1) RS67295B1 (https=)
SI (1) SI4034122T1 (https=)
SM (1) SMT202500493T1 (https=)
WO (1) WO2021062264A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) * 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) * 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin

Also Published As

Publication number Publication date
SMT202500493T1 (it) 2026-01-12
SI4034122T1 (sl) 2025-12-31
IL291565B1 (en) 2026-04-01
AU2020353676A1 (en) 2022-04-14
HUE073483T2 (hu) 2026-01-28
FI4034122T3 (fi) 2025-10-08
IL291565A (en) 2022-05-01
DK4034122T3 (da) 2025-09-15
LT4034122T (lt) 2025-11-10
JP2025111476A (ja) 2025-07-30
JP2022549834A (ja) 2022-11-29
JOP20220042A1 (ar) 2023-01-30
HRP20251268T1 (hr) 2025-12-05
PT4034122T (pt) 2025-09-18
WO2021062264A1 (en) 2021-04-01
MX2022003585A (es) 2022-04-19
CN114650825A (zh) 2022-06-21
EP4034122A1 (en) 2022-08-03
ES3041002T3 (en) 2025-11-06
JP7661315B2 (ja) 2025-04-14
US20220362249A1 (en) 2022-11-17
EP4034122B1 (en) 2025-08-13
RS67295B1 (sr) 2025-11-28
BR112022003719A2 (pt) 2022-05-31
KR20220070477A (ko) 2022-05-31
PL4034122T3 (pl) 2026-01-26

Similar Documents

Publication Publication Date Title
EP4034122B1 (en) Methods for treating hyperphenylalaninemia
JP7442095B2 (ja) ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法
US20230321021A1 (en) Methods of normalizing amino acid metabolism
JP2023116556A (ja) セピアプテリンを含む医薬組成物及びその使用
JP5921664B2 (ja) 皮膚の乾燥予防または改善用経口剤
EP3801534B1 (en) Treatment of phenylketonuria with sepiapterin
RS65874B1 (sr) Primena sepiapterina bez hrane za upotrebu u postupku za povećanje izloženosti plazme sepiapterinu
US20210205334A1 (en) Methods and Composition for Increasing Muscle Protein Synthesis and/or Functional Strength in Mammals
EP2990048B1 (en) Nitric oxide concentration elevating agent
US12324796B2 (en) Sleep-improving compositions and methods of use
AU2020353676B2 (en) Methods for treating hyperphenylalaninemia
HK40081378A (en) Methods for treating hyperphenylalaninemia
HK40081378B (en) Methods for treating hyperphenylalaninemia
EA052959B1 (ru) Способы лечения гиперфенилаланинемии
EA047419B1 (ru) Способы лечения гиперфенилаланинемии
CA3165636A1 (en) Methods for treating parkinson's disease with sepiapterin
JP2024506336A (ja) 膠芽腫の治療方法
WO2024123738A1 (en) Compositions and methods for treating diseases responsive to akg-vitamin b coadministration
WO2022173823A1 (en) Methods for treating covid-19 with sepiapterin
US20070072910A1 (en) Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240823

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240823

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240823

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241002

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241203

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250414

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250814

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905